cannot make heads or tails w/r to below two items, the first an e-mail, and the second, the Bloomberg report in question
From e-mail from a medical person
This newspaper report by Bloomberg published in the ST is misleading and unethical because it selectively quotes a research but leaves out pertinent information. The newspaper says researchers from Hong Kong has found that 2 doses of vaccine from Sinovac or Pfizer does not produce enough neutralizing antibodies to protect against Omicron. However, for people who have had 2 doses of Pfizer’s vaccine, a booster using the same vaccine “raised protection to adequate levels”. For people who have had 2 doses of Sinovac’s vaccine, a booster using the same vaccine “did not produce sufficient levels of neutralizing antibodies to protect against Omicron”. However, a booster using Pfizer’s vaccine produced “significantly improved protective levels of neutralizing antibodies against Omicron”. The newspaper comments that the results are a “blow to those who have received Sinovac’s vaccine”. *But what the newspaper did not mention is that the researchers found that Sinovac’s vaccine produces much higher levels of T-cell responses which help in destroying infected cells and are thus important in limiting severity and fatal outcomes. The researchers go on to say that this finding is consistent with high levels of protection against hospitalization and death in Sinovac’s vaccine observed in Chile and Turkey despite lower antibody neutralization.* *And this last part in the research is crucial, but the newspaper conveniently it left out. Studies of re-infection in animals have found that high levels of T-cell responses can compensate for inadequate neutralizing antibody response and are able to protect against different variants of concern. This, the researchers say, is the advantage of inactivated virus vaccine (Sinovac and Sinopharm) as they contain antigens that elicit strong T-cell response and may confer immunity.* Given the headline of the newspaper, “3 doses of Sinovac fail to protect against variant : Researchers”, most people would go away thinking that Sinovac’s vaccine is useless, which is not what the researchers are saying. Newspapers are ultimately owned by entities with vested interest. The events they report, the slant in the analysis they carry as well as the one-sidedness of their reports, reveal the agendas of their masters.
From Bloomberg
bloomberg.com
Prognosis
Three Sinovac Doses Fail to Protect Against Omicron in Study
By
Jinshan Hong
+Follow
23 December 2021, 16:30 GMT+8
Updated on 23 December 2021, 17:00 GMT+8
- Chinese shot is one of the most widely used globally
- Vaccination plus a booster yielded few neutralizing antibodies
Two doses and a booster of the Covid-19 vaccine made by China’s Sinovac Biotech Ltd., one of the most widely used in the world, didn’t produce sufficient levels of neutralizing antibodies to protect against the omicron variant, a laboratory study found.
The research suggests that people who’ve received Sinovac’s shot, known as CoronaVac, should seek out a different vaccine for their booster: Getting Germany’s BioNTech SE’s messenger RNA as a third dose saw those previously fully vaccinated with CoronaVac significantly improve in protective levels of antibodies against omicron, according to the study from the University of Hong Kong and The Chinese University of Hong Kong.
Two doses of the BioNTech shot, known as Comirnaty, was also insufficient, though adding a booster of the same type raised protection to adequate levels, the researchers said in a statement.
Graph showing virus neutralizing antibody levels in the blood of those immunized and boosted with Comirnaty (BioNTech) or CoronaVac (Sinovac) vaccines.
Source: University of Hong Kong
While much is still unknown about how Sinovac’s shot holds up to omicron -- including how T cells, the immune system’s weapon against virus-infected cells, will respond -- the initial results are a blow to those who have received CoronaVac. There have been more than 2.3 billion doses of the shot produced and shipped out, mostly in China and the developing world.
With omicron seen to be about 70 times more transmissible than the delta variant, the prospect of having to roll out different boosters or even re-vaccinate with a more omicron-specific vaccine will set back the world’s efforts to exit the pandemic.
Last week, Sinovac released lab studies saying 94% of people getting three doses generated neutralizing antibodies, though it didn’t say what level. The Hong Kong researchers set a threshold for what they considered a sufficient level of antibodies for protection based on earlier studies published in the journal Nature Medicine.
Sinovac representatives didn’t immediately respond to calls seeking comment.
The research, led by Malik Peiris and David Hui, examined the production of virus neutralizing antibodies in the blood of people vaccinated with the two shots currently in use in Hong Kong. They confirm two doses of either vaccine wasn’t sufficient to fend off omicron.
The news comes as Hong Kong’s medical advisers cleared the way for adults in the city to receive a booster shot, no matter which vaccine they initially received. The new study suggests there are critical differences between them.
The findings are bad news for China, which has managed to insulate the vast majority of its people from Covid-19 with closed borders and strict containment measures, but now faces the challenge of keeping omicron out. The government has given out 2.6 billion homegrown shots -- many of them CoronaVac -- to its population of 1.4 billion people, but will likely have to develop and roll out new vaccines before it can shift away from its isolationist stance. |
